EGFR and non-small cell lung carcinoma: Currently available first-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations include EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib, erlotinib, afatinib, and more recently, osimertinib [3, 4].